Ponatinib HCl
编号: 17030607
Cas号: 1114544-31-8
纯度: 98%
Ponatinib, also known as AP24534 is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosomeCpositive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors. Ponatinib was approved in 2012.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Ponatinib HCl |
|---|---|
| Iupac 化学名称 | 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide hydrochloride |
| 同义词 | AP24534; AP-24534; AP 24534; Ponatinib HCl; Ponatinib hydrochloride. trade name Iclusig |
| 英文同义词 | AP24534; AP-24534; AP 24534; Ponatinib HCl; Ponatinib hydrochloride. trade name Iclusig |
| 分子式 | C29H28ClF3N6O |
| 分子量 | 569.0292 |
| Smile | Cl.N=1C=C(N2N=CC=CC21)C#CC=2C=C(C(=O)NC1=CC(=C(C=C1)CN1CCN(CC1)C)C(F)(F)F)C=CC2C |
| InChiKey | BWTNNZPNKQIADY-UHFFFAOYSA-N |
| InChi | InChI=1S/C29H27F3N6O.ClH/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37;/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39);1H |
| Cas号 | 1114544-31-8 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
